Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study

BackgroundFor patients who have contraindications to or have failed checkpoint inhibitors, chemotherapy remains the standard second-line option to treat non-oncogene-addicted advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of S-1-based non-platinu...

詳細記述

書誌詳細

出版年:	Frontiers in Oncology
主要な著者:	Xiangling Wang, Ting Wang, Yunxia Chu, Jie Liu, Cuihua Yi, Xuejun Yu, Yonggang Wang, Tianying Zheng, Fangli Cao, Linli Qu, Bo Yu, Huayong Liu, Fei Ding, Shuang Wang, Xiangbo Wang, Jing Hao, Xiuwen Wang
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2023-03-01
主題:	non-small cell lung cancer second-line treatment S-1 gemcitabine docetaxel
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1089234/full